Recommendation Grading
Grade
Definition
I
Randomized controlled trials
II-1
Controlled trials without randomization
II-2
Cohort or case-control analytic studies
II-3
Multiple time series, dramatic uncontrolled experiments
III
Opinions of respected authorities, descriptive epidemiology
Abbreviations
ADV, adefovir; AFP, alpha fetoprotein; ALT, alanine aminotransferase; anti-HBc,
hepatitis B core antibody; anti-HBe, antibody to hepatitis B e antigen; anti-HBs,
hepatitis B surface antibody; AST, aspartate aminotransferase; ClCr, creatinine
clearance; ETV, entecavir; HAART, highly active antiretroviral therapy; HBeAg,
hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus;
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; HIV,
human immunodeficiency virus; IFN-��, interferon-alpha; IU, international unit; LAM,
lamivudine; LdT, telbivudine; MU, million units; NA, nucleoside analogues; PCR,
polymerase chain reaction; pegIFN-��, pegylated interferon-alpha; q, every; qd, daily;
TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal
Source
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-662.
Disclaimer
This Guideline attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. This Guideline
should not be considered exclusive of other methods of care reasonably directed at obtaining the
same results. The ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician after consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated
with the distributor of this clinical reference tool.
HEB10122a
5740 Executive Drive��� Suite 218
Baltimore, MD 21228���
TEL: 410-869-3332��� ������ FAX: 410-744-2150���
For additional copies: orders@GuidelineCentral.com
Copyright �� 2012 All rights reserved
